OS: Key secondary endpoint
All patients
100
80
60
40
20
0
0 4 8 12 16 20 24 28 32 36
655
607
516
444
374
316
271
234
200
171
147
130
106
88
67
51
34
27
14
659
600
511
411
344
290
250
207
162
144
120
100
91
74
58
51
28
25
13
Probability of survival (%)
Number at risk
Nintedanib
Placebo
Time (months)
Nintedanib +
docetaxel
Placebo +
docetaxel
Median, mo
10.1
9.1
HR (95% CI)
0.94
(0.83–1.05)
p value
0.2720
Reck M,
et al
.
Lancet Oncol
. 2014;15:143-55.
